Last week, the DCVMN Regulatory Working Group, comprised of experts from member companies, gathered in Brussels for a dynamic three-day workshop with a special focus on Next-Generation Sequencing (NGS) technology. This innovative technology offers significant advantages to the vaccine industry.
Key discussions included:
🔹 Transition to Non-Animal Testing: Emphasizing the importance of collaboration between technical development, manufacturing, QC, and regulatory affairs departments. Dialogue and alignment are crucial for building trust in novel approaches that can speed up vaccine release times and reduce costs.
🔹 Regulatory and Industry Insights: Members exchanged valuable experiences and suggestions for the validation process of NGS technology with regulators and other industry representatives.
🔹 Advancing WG Objectives: Significant progress was made towards achieving the action plan goals, including promoting the reliance and broader adoption of TRS 993 in the LATAM region and addressing pharmacopeial harmonization.
A big thank you to PATH for their continued support in DCVMN’s working group activities. Additionally, we extend our gratitude to Sciensano for hosting the site visit, which provided the Working Group with valuable insights into the daily application of NGS. This workshop was a testament to the power of collaboration and innovation in advancing vaccine quality and accessibility within the DCVMN Network.
